Epoetin alfa--focus on optimal hematocrit. Case study of the anemic patient.
Epoetin alfa therapy has dramatically improved therapeutic responses and outcomes for anemic patients with end-stage renal disease. This article examines clinical evidence supporting the correlation between patient outcomes and a higher hematocrit and addresses some of the barriers that may hinder optimal patient outcomes.
Hendrix
W R
WR
D000203:Activities of Daily Living; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008875:Middle Aged; D011788:Quality of Life
D004921:Erythropoietin